Brand Name Equivalent: Alkeran® (Alkeran is a registered trademark of Par Pharmaceutical, Inc.)
Therapeutic Category: Oncology
NDC #25021 |
Description | Strength | Fill Volume |
Concentration | Container Size |
Closure | Unit of Sale |
258-61 | glass vial | 50 mg | N/A | N/A | 15 mL | 20 mm | 1 |
WARNING
Melphalan Hydrochloride for Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous to oral melphalan have shown more myelosuppression with the intravenous formulation. Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the intravenous formulation. Melphalan is leukemogenic in humans. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.